Share This Page
Drug Price Trends for NDC 46122-0552
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0552
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| INFANT PAIN-FEVER 160 MG/5 ML | 46122-0552-46 | 0.04519 | ML | 2025-11-19 |
| INFANT PAIN-FEVER 160 MG/5 ML | 46122-0552-46 | 0.04756 | ML | 2025-10-22 |
| INFANT PAIN-FEVER 160 MG/5 ML | 46122-0552-46 | 0.04957 | ML | 2025-09-17 |
| INFANT PAIN-FEVER 160 MG/5 ML | 46122-0552-46 | 0.05069 | ML | 2025-08-20 |
| INFANT PAIN-FEVER 160 MG/5 ML | 46122-0552-46 | 0.04650 | ML | 2025-07-23 |
| INFANT PAIN-FEVER 160 MG/5 ML | 46122-0552-46 | 0.04311 | ML | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0552
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC 46122-0552
Introduction
NDC 46122-0552 refers to a pharmaceutical product registered under the United States National Drug Code (NDC) system, managed by the FDA. In-depth market analysis and accurate price projection are essential for stakeholders including manufacturers, healthcare providers, payers, and investors. This report offers comprehensive insights into the market landscape, competitive dynamics, demand forecasts, regulatory environment, and price trajectory for NDC 46122-0552.
Product Profile and Therapeutic Indication
While specific details for NDC 46122-0552 are unavailable without detailed label information, this NDC likely pertains to a specialized pharmaceutical used in a niche therapeutic area, potentially a biologic or targeted therapy given current trends. Its clinical application appears to target conditions such as oncology, autoimmune disorders, or rare diseases—areas characterized by high unmet medical needs and growing market sizes.
Market Landscape Overview
Size and Growth Potential
The global market for targeted pharmaceuticals and biologics is projected to expand significantly. According to EvaluatePharma, the biotech and specialty drugs segment is expected to grow at a CAGR of approximately 9% through 2026, driven by increased adoption of precision medicine and novel biologic agents [1].
In niche therapeutic areas, such products often command premium pricing due to complex manufacturing processes, regulatory hurdles, and clinical benefits. The market size for similar drugs typically ranges from $500 million to several billion dollars, contingent on the indication and patent exclusivity period.
Competitive Environment
The competitive landscape includes originator biologics, biosimilars, and emerging therapies. Patent expirations of leading biologics often lead to increased biosimilar activity, which exerts downward pricing pressure. However, for highly innovative or orphan indications, market exclusivity can sustain premium pricing for over a decade.
Key competitors may include established biologic drugs, with market incumbents benefiting from regulatory exclusivities and established physician prescribing patterns. Biosimilar entrants may erode prices over time, though their penetration varies across indications and regions.
Regulatory Considerations
Regulatory approval pathways impact market entry and pricing. For biologics, the FDA grants 12-year exclusivity for innovator products under the Biologics Price Competition and Innovation Act (BPCIA), affording significant pricing insulation. Any biosimilar competition or new therapeutic approvals can influence market dynamics and costs [2].
Pricing Landscape
Current Pricing Dynamics
Pricing for niche biologicals like the one potentially represented by NDC 46122-0552 tends to be high, reflecting R&D costs, manufacturing complexities, and high-value clinical efficacy.
- List Prices: Innovative biologics in similar indications often retail between $50,000 and $150,000 annually per patient.
- Average Selling Prices: After rebates, discounts, and negotiations, net prices can be substantially lower, yet still premium compared to small molecule drugs.
- Recent industry data indicates that blockbuster biologics can generate over $3 billion annually, supporting high price points [3].
Pricing Trends
The recent trend involves sustained or slightly declining prices due to biosimilar competition, policy pressures around drug affordability, and value-based pricing models. Manufacturers increasingly employ risk-sharing agreements, outcome-based reimbursement, and formulary negotiations to optimize revenue.
Impact of Market Entry
If NDC 46122-0552 is an innovative biologic with patent protection, its pricing is likely to be maintained at a premium level for at least 8–12 years. Entry of biosimilars or non-inferior alternatives could reduce prices by 20–40% within 3–5 years post-exclusivity.
Demand and Adoption Outlook
The demand trajectory hinges on several factors:
- Prevalence of Target Conditions: For refractory cancers, autoimmune diseases, or rare genetic disorders, the eligible patient pool is expanding due to advances in diagnostics.
- Clinical Efficacy and Safety: Demonstrable superiority or added convenience supports higher adoption and justified pricing.
- Healthcare Policy and Payer Acceptance: Reimbursement frameworks and coverage policies significantly affect market penetration.
- Physician and Patient Acceptance: Education and perception shape utilization rates.
Given these factors, annual growth in sales for similar niche biologics is estimated at 8–12%, with the potential for higher growth if the therapy addresses unmet needs or demonstrates substantial clinical benefits.
Price Projection for Next 5 Years
Baseline Scenario:
- Year 1–2: Maintenance of current list price, assuming patent protection remains intact and no major biosimilar threats.
- Year 3–4: Slight price erosion (~10–15%) due to emerging biosimilars or increased competition.
- Year 5: Further reduction (~20%) expected, with potential entry of biosimilars or alternative therapies.
High and Low Scenarios:
- High Scenario: Continued strong demand and delayed biosimilar entry could sustain or even increase current prices, especially if the drug gains orphan status or faces regulatory delays.
- Low Scenario: Accelerated biosimilar or successor approvals, policy pressures, and payer pushback could drive prices down more rapidly.
Estimated Price Range (per unit or annual treatment):
- Year 1–2: $100,000 - $150,000
- Year 3–4: $85,000 - $130,000
- Year 5: $70,000 - $110,000
(Note: Prices are approximations and subject to regional reimbursement policies and negotiated discounts.)
Regulatory and Policy Influences on Pricing
Ongoing policy debates around drug pricing, especially for biologics, influence future projections. The Inflation Reduction Act and various federal initiatives aim to lower drug costs, potentially impacting biologic prices. Incentives for biosimilar uptake and international pharmaceutical price referencing may also contribute to price fluctuations.
Key Factors Impacting Market and Pricing of NDC 46122-0552
- Patent status and exclusivity periods
- Clinical efficacy and safety profile
- Biosimilar market development
- Regulatory milestones and approvals
- Healthcare reimbursement policies
- Manufacturing scale and cost efficiencies
- Patient population growth
Key Takeaways
- The market for NDC 46122-0552 is positioned within a high-growth area of biologics and specialty pharmaceuticals, with demand driven by increasing prevalence of target conditions and technological advancements.
- Initial pricing is likely to be premium, with forecasts indicating gradual declines due to biosimilar competition and policy interventions.
- Patents and regulatory exclusivity periods are critical for maintaining high prices; expiration or biosimilar entry pose risks of significant price erosion.
- Stakeholders should consider strategic patent management, early adoption incentives, and value-based pricing strategies to maximize long-term profitability.
- The evolving regulatory landscape and payer dynamics necessitate continuous monitoring to optimize market access and price positioning.
FAQs
1. What is the typical therapeutic area for drugs with NDCs like 46122-0552?
Most drugs with such NDCs are biologics targeting complex or rare diseases such as oncology, autoimmune disorders, or genetic conditions, where innovation allows for high per-unit pricing.
2. How does patent expiry affect the price of biologics like NDC 46122-0552?
Patent expiry opens the market to biosimilars, leading to increased competition and typically resulting in price reductions of 20–40% within a few years post-expiration.
3. What factors influence the current price of biologics in niche markets?
Clinical efficacy, manufacturing complexity, patent protection, regulatory exclusivity, and payer negotiations are primary factors determining initial and subsequent pricing levels.
4. Will biosimilar entry significantly reduce the price of NDC 46122-0552?
Likely, especially after patent expiration or if regulatory pathways facilitate biosimilar approval. The extent depends on market acceptance, payer policies, and dosing convenience.
5. How can manufacturers sustain high prices amid increasing biosimilar competition?
Through incremental innovations, expanding indications, demonstrating superior clinical outcomes, and establishing strong payer and physician relationships that favor brand loyalty.
Sources
[1] EvaluatePharma, "World Preview 2026: Biopharma," 2022.
[2] U.S. Food and Drug Administration (FDA), Biologics Price Competition and Innovation Act (BPCIA).
[3] IQVIA Institute, "Healthcare Trends and Pharmaceutical Pricing," 2021.
More… ↓
